All In Biotech

Drug Trial Radar · NCT06415279

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Clinical Evaluation of the Sebum Reduction Induced by Clascoterone Cream 1%

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Feb 14, 2024

Primary completion

Feb 12, 2025

Study completion Feb 12, 2025

Sponsor

Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c. acnes, the bacteria die, and acne resolves. An FDA approved acne medication consisting of clascoterone cream 1% is believed to effectively treat acne due to a decrease in sebum production. This mechanism of action has been postulated based on efficacy observed in the phase III trials that lead to its approval. This research aims to demonstrate the effect of clascoterone cream 1% in sebum reduction.

Conditions

  • Acne Vulgaris

Interventions

  • Winlevi (clascoterone) 1% creamDrug

    Twice daily (BID) dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Efficacy Endpoint is the Change in Causal Sebum Measurements From the Forehead Obtained With a Sebumeter During the Study.Time frame: Weeks 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Consulting Services, PLLC

    High Point, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.